Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: Implication for optimal age of human papillomavirus vaccination

Chih Jung Chen, Raphael P. Viscidi, Chih Hsien Chuang, Yhu Chering Huang, Cheng Hsun Chiu, Tzou Yien Lin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The optimal age for administration of recently approved prophylactic human papillomavirus (HPV) vaccines remains undetermined. Objectives: The aim of the study was to explore the age-specific seroprevalence of HPV 16 and 18 in the general population to design an HPV vaccination campaign for Taiwan. Study design: HPV seroprevalence was assessed by virus-like particle (VLP)-based ELISA in 1702 plasma samples collected in 1999. Results: The sample population consisted of 1000 (58.8%) females and 702 (41.2%) males; age ranged from 17 days to 86 years. The age-specific distributions reveal a significant rise in HPV 16 seropositivity commencing at 19-25 years of age and peaking at >60 years. The trend of seropositivity increase with age was also highly significant for HPV 18 (PTrend < 0.0001). Males had lower overall seroprevalence in gender comparison (7.6% versus 3.85% for HPV 16, 3.9% versus 2.71% for HPV 18), were older at seroconversion (19-25 years versus 26-30 years) with a more obvious seropositivity nadir in middle age. Conclusion: The age-specific seroprevalence of HPV 16 and 18 increases in young adults after the age of 18 years, with gender distribution varying. We conclude that the optimal age for universal HPV vaccination in Taiwan is 15 years or below.

Original languageEnglish
Pages (from-to)126-130
Number of pages5
JournalJournal of Clinical Virology
Volume38
Issue number2
DOIs
Publication statusPublished - Feb 2007
Externally publishedYes

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Seroepidemiologic Studies
Taiwan
Vaccination
Population
Papillomavirus Vaccines
Immunization Programs
Age Distribution
Virion
Young Adult
Enzyme-Linked Immunosorbent Assay

Keywords

  • Human papillomavirus
  • Seroprevalence
  • Taiwan

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan : Implication for optimal age of human papillomavirus vaccination. / Chen, Chih Jung; Viscidi, Raphael P.; Chuang, Chih Hsien; Huang, Yhu Chering; Chiu, Cheng Hsun; Lin, Tzou Yien.

In: Journal of Clinical Virology, Vol. 38, No. 2, 02.2007, p. 126-130.

Research output: Contribution to journalArticle

Chen, Chih Jung ; Viscidi, Raphael P. ; Chuang, Chih Hsien ; Huang, Yhu Chering ; Chiu, Cheng Hsun ; Lin, Tzou Yien. / Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan : Implication for optimal age of human papillomavirus vaccination. In: Journal of Clinical Virology. 2007 ; Vol. 38, No. 2. pp. 126-130.
@article{50f64b8b471d4f1aa051cf883d8b2f03,
title = "Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: Implication for optimal age of human papillomavirus vaccination",
abstract = "Background: The optimal age for administration of recently approved prophylactic human papillomavirus (HPV) vaccines remains undetermined. Objectives: The aim of the study was to explore the age-specific seroprevalence of HPV 16 and 18 in the general population to design an HPV vaccination campaign for Taiwan. Study design: HPV seroprevalence was assessed by virus-like particle (VLP)-based ELISA in 1702 plasma samples collected in 1999. Results: The sample population consisted of 1000 (58.8{\%}) females and 702 (41.2{\%}) males; age ranged from 17 days to 86 years. The age-specific distributions reveal a significant rise in HPV 16 seropositivity commencing at 19-25 years of age and peaking at >60 years. The trend of seropositivity increase with age was also highly significant for HPV 18 (PTrend < 0.0001). Males had lower overall seroprevalence in gender comparison (7.6{\%} versus 3.85{\%} for HPV 16, 3.9{\%} versus 2.71{\%} for HPV 18), were older at seroconversion (19-25 years versus 26-30 years) with a more obvious seropositivity nadir in middle age. Conclusion: The age-specific seroprevalence of HPV 16 and 18 increases in young adults after the age of 18 years, with gender distribution varying. We conclude that the optimal age for universal HPV vaccination in Taiwan is 15 years or below.",
keywords = "Human papillomavirus, Seroprevalence, Taiwan",
author = "Chen, {Chih Jung} and Viscidi, {Raphael P.} and Chuang, {Chih Hsien} and Huang, {Yhu Chering} and Chiu, {Cheng Hsun} and Lin, {Tzou Yien}",
year = "2007",
month = "2",
doi = "10.1016/j.jcv.2006.12.004",
language = "English",
volume = "38",
pages = "126--130",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan

T2 - Implication for optimal age of human papillomavirus vaccination

AU - Chen, Chih Jung

AU - Viscidi, Raphael P.

AU - Chuang, Chih Hsien

AU - Huang, Yhu Chering

AU - Chiu, Cheng Hsun

AU - Lin, Tzou Yien

PY - 2007/2

Y1 - 2007/2

N2 - Background: The optimal age for administration of recently approved prophylactic human papillomavirus (HPV) vaccines remains undetermined. Objectives: The aim of the study was to explore the age-specific seroprevalence of HPV 16 and 18 in the general population to design an HPV vaccination campaign for Taiwan. Study design: HPV seroprevalence was assessed by virus-like particle (VLP)-based ELISA in 1702 plasma samples collected in 1999. Results: The sample population consisted of 1000 (58.8%) females and 702 (41.2%) males; age ranged from 17 days to 86 years. The age-specific distributions reveal a significant rise in HPV 16 seropositivity commencing at 19-25 years of age and peaking at >60 years. The trend of seropositivity increase with age was also highly significant for HPV 18 (PTrend < 0.0001). Males had lower overall seroprevalence in gender comparison (7.6% versus 3.85% for HPV 16, 3.9% versus 2.71% for HPV 18), were older at seroconversion (19-25 years versus 26-30 years) with a more obvious seropositivity nadir in middle age. Conclusion: The age-specific seroprevalence of HPV 16 and 18 increases in young adults after the age of 18 years, with gender distribution varying. We conclude that the optimal age for universal HPV vaccination in Taiwan is 15 years or below.

AB - Background: The optimal age for administration of recently approved prophylactic human papillomavirus (HPV) vaccines remains undetermined. Objectives: The aim of the study was to explore the age-specific seroprevalence of HPV 16 and 18 in the general population to design an HPV vaccination campaign for Taiwan. Study design: HPV seroprevalence was assessed by virus-like particle (VLP)-based ELISA in 1702 plasma samples collected in 1999. Results: The sample population consisted of 1000 (58.8%) females and 702 (41.2%) males; age ranged from 17 days to 86 years. The age-specific distributions reveal a significant rise in HPV 16 seropositivity commencing at 19-25 years of age and peaking at >60 years. The trend of seropositivity increase with age was also highly significant for HPV 18 (PTrend < 0.0001). Males had lower overall seroprevalence in gender comparison (7.6% versus 3.85% for HPV 16, 3.9% versus 2.71% for HPV 18), were older at seroconversion (19-25 years versus 26-30 years) with a more obvious seropositivity nadir in middle age. Conclusion: The age-specific seroprevalence of HPV 16 and 18 increases in young adults after the age of 18 years, with gender distribution varying. We conclude that the optimal age for universal HPV vaccination in Taiwan is 15 years or below.

KW - Human papillomavirus

KW - Seroprevalence

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=33846214271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846214271&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2006.12.004

DO - 10.1016/j.jcv.2006.12.004

M3 - Article

C2 - 17210269

AN - SCOPUS:33846214271

VL - 38

SP - 126

EP - 130

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 2

ER -